| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Zi-Zhen Si, Chen-Jun Zou, Xi Mei, Xiao-Fang Li, Hu Luo, Yao Shen, Jun Hu, Xing-Xing Li, Lun Wu, Yu Li. Targeting neuroinflammation in Alzheimer's disease: from mechanisms to clinical applications. Neural regeneration research. vol 18. issue 4. 2022-10-07. PMID:36204826. |
an increasing body of evidence suggests that neuroinflammation plays an important role in alzheimer's disease pathogenesis, alongside the classical pathological hallmarks such as misfolded and aggregated proteins (e.g., amyloid-beta and tau). |
2022-10-07 |
2023-08-14 |
Not clear |
| Umang Shah, Aneri Shah, Sandip Patel, Alkesh Patel, Mehul Patel, Nilay Solanki, Swayamprakash Patel, Ashish Patel, Veena Patel, Bhavesh Pate. Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment. CNS & neurological disorders drug targets. 2022-10-06. PMID:36200162. |
future directions in the research and treatment of alzheimer's disease patients include the use of antisense oligonucleotides (aso) to change target expression, and researchers discovered decreased markers of oxidative stress in tissues affected by tau pathology in response to rna interference treatment. |
2022-10-06 |
2023-08-14 |
Not clear |
| Ihab Hajjar, Zhiyi Yang, Maureen Okafor, Chang Liu, Teresa Waligorska, Felicia C Goldstein, Leslie M Sha. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors. JAMA network open. vol 5. issue 10. 2022-10-06. PMID:36201209. |
differences in cerebrospinal fluid (csf) tau alzheimer dementia (ad) biomarkers by self-identified race have been observed in prior studies. |
2022-10-06 |
2023-08-14 |
Not clear |
| Pablo Cisternas, Xavier Taylor, Pablo Martinez, Orlando Maldonado, Nur Jury, Cristian A Lasagna-Reeve. The reduction of astrocytic tau prevents amyloid-β-induced synaptotoxicity. Brain communications. vol 4. issue 5. 2022-10-05. PMID:36196088. |
alzheimer's disease is a neurological disorder characterized by the overproduction and aggregation of amyloid-beta and the phosphorylation and intraneuronal accumulation of tau. |
2022-10-05 |
2023-08-14 |
Not clear |
| Pablo Cisternas, Xavier Taylor, Pablo Martinez, Orlando Maldonado, Nur Jury, Cristian A Lasagna-Reeve. The reduction of astrocytic tau prevents amyloid-β-induced synaptotoxicity. Brain communications. vol 4. issue 5. 2022-10-05. PMID:36196088. |
reducing endogenous astrocytic tau expression could be a potential strategy to prevent synaptic damage in alzheimer's disease and other neurological conditions. |
2022-10-05 |
2023-08-14 |
Not clear |
| Yan Yan, Xinming Wang, Dale Chaput, Min-Kyoo Shin, Yeojung Koh, Li Gan, Andrew A Pieper, Jung-A A Woo, David E Kan. X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women. Cell. 2022-10-05. PMID:36198316. |
although women experience significantly higher tau burden and increased risk for alzheimer's disease (ad) than men, the underlying mechanism for this vulnerability has not been explained. |
2022-10-05 |
2023-08-14 |
mouse |
| Yu Guo, Yu-Xiang Yang, Ya-Ru Zhang, Yu-Yuan Huang, Ke-Liang Chen, Shi-Dong Chen, Prof Qiang Dong, Jin-Tai Y. Genome-wide association study of brain tau deposition as measured by Neurobiology of aging. vol 120. 2022-10-04. PMID:36195041. |
genome-wide association study of brain tau deposition as measured by the related genetic variants of tau deposition, a seminal pathological hallmark of alzheimer's disease, remain poorly understood. |
2022-10-04 |
2023-08-14 |
Not clear |
| Pariya Khodabakhsh, Maryam Bazrgar, Fatemeh Mohagheghi, Siavash Parvardeh, Abolhassan Ahmadian. MicroRNA-140-5p inhibitor attenuates memory impairment induced by amyloid-ß oligomer in vivo possibly through Pin1 regulation. CNS neuroscience & therapeutics. 2022-10-03. PMID:36184817. |
the peptidyl-prolyl cis/trans isomerase, pin1, has a protective role in age-related neurodegeneration by targeting different phosphorylation sites of tau and the key proteins required to produce amyloid-β, which are the well-known molecular signatures of alzheimer's disease (ad) neuropathology. |
2022-10-03 |
2023-08-14 |
rat |
| Karl Hansson, Rahil Dahlén, Oskar Hansson, Elin Pernevik, Ross Paterson, Jonathan M Schott, Nadia Magdalinou, Henrik Zetterberg, Kaj Blennow, Johan Gobo. Corrigendum to "Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease" [Clin. Mass Spectrom. 14 (Part B) (2019) 74-82]. Journal of mass spectrometry and advances in the clinical lab. vol 26. 2022-10-03. PMID:36187744. |
corrigendum to "use of the tau protein-to-peptide ratio in csf to improve diagnostic classification of alzheimer's disease" [clin. |
2022-10-03 |
2023-08-14 |
Not clear |
| Yukiko Hori, Youhei Sohma, Motomu Kanai, Taisuke Tomit. Promotion in the Clearance of Aggregated Aβ In Vivo Using Amyloid Selective Photo-Oxygenation Technology. Neuroscience insights. vol 17. 2022-10-03. PMID:36189373. |
alzheimer's disease (ad) is characterized by the aggregation and deposition of 2 amyloid proteins: amyloid β peptide (aβ) and tau protein. |
2022-10-03 |
2023-08-14 |
mouse |
| Martina P Morawe, Fan Liao, Willi Amberg, Jeroen van Bergeijk, Rui Chang, Mary Gulino, Caitlin Hamilton, Carolin Hoft, Casey Lumpkin, Bryan Mastis, Emily McGlame, Judith Nuber, Christian Plaas, Brinda Ravikumar, Kaushambi Roy, Marion Schanzenbächer, Joseph Tierno, Viktor Lakics, Tammy Dellovade, Matthew Townsen. Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain. European journal of pharmacology. 2022-10-03. PMID:36191631. |
in this study we aimed to reduce tau pathology, a hallmark of alzheimer's disease (ad), by activating mtor-dependent autophagy in a transgenic mouse model of tauopathy by long-term dosing of animals with mtor-inhibitors. |
2022-10-03 |
2023-08-14 |
mouse |
| Etsuko Imabayashi, Yuji Saitoh, Tadashi Tsukamoto, Masuhiro Sakata, Harumasa Takan. Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18F-THK5351. Clinical nuclear medicine. 2022-09-30. PMID:36179331. |
combination of astrogliosis and phosphorylated tau for the preclinical diagnosis of alzheimer disease using 3-dimensional stereotactic surface projection images with 18f-thk5351. |
2022-09-30 |
2023-08-14 |
Not clear |
| Etsuko Imabayashi, Yuji Saitoh, Tadashi Tsukamoto, Masuhiro Sakata, Harumasa Takan. Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18F-THK5351. Clinical nuclear medicine. 2022-09-30. PMID:36179331. |
the alzheimer disease (ad) brain is characterized microscopically by the presence of extracellular amyloid plaques and intraneuronal neurofibrillary tangles consisting of phosphorylated tau aggregations. |
2022-09-30 |
2023-08-14 |
Not clear |
| Helena Gossye, Sara Van Mossevelde, Anne Sieben, Maria Bjerke, Elisabeth Hendrickx Van de Craen, Julie van der Zee, Peter P De Deyn, Jan De Bleecker, Jan Versijpt, Jenneke van den Ende, Olivier Deryck, Paul Bourgeois, Jean Christophe Bier, Maarten Goethals, Rik Vandenberghe, Sebastiaan Engelborghs, Christine Van Broeckhove. Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum. Brain : a journal of neurology. 2022-09-29. PMID:36171642. |
the missense mutation p.r406w in microtubule-associated protein tau leads to frontotemporal lobar degeneration with an amnestic, alzheimer's disease-like phenotype with an autosomal dominant pattern of inheritance. |
2022-09-29 |
2023-08-14 |
Not clear |
| M-A de Fisenne, Z Yilmaz, R De Decker, V Suain, L Buée, K Ando, J-P Brion, K Lero. Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in mouse models. Neurobiology of disease. 2022-09-26. PMID:36154878. |
alzheimer phf-tau aggregates do not spread tau pathology to the brain via the retino-tectal projection after intraocular injection in mouse models. |
2022-09-26 |
2023-08-14 |
mouse |
| M-A de Fisenne, Z Yilmaz, R De Decker, V Suain, L Buée, K Ando, J-P Brion, K Lero. Alzheimer PHF-tau aggregates do not spread tau pathology to the brain via the Retino-tectal projection after intraocular injection in mouse models. Neurobiology of disease. 2022-09-26. PMID:36154878. |
neurofibrillary tangles (nft), a neuronal lesion found in alzheimer's disease (ad), are composed of fibrillary aggregates of modified forms of tau proteins. |
2022-09-26 |
2023-08-14 |
mouse |
| X Anton Alvarez, Charisse N Winston, James W Barlow, Floyd M Sarsoza, Irene Alvarez, Manuel Aleixandre, Carlos Linares, Manuel García-Fantini, Birgit Kastberger, Stefan Winter, Robert A Rissma. Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil. Journal of Alzheimer's disease : JAD. 2022-09-26. PMID:36155516. |
modulation of amyloid-β and tau in alzheimer's disease plasma neuronal-derived extracellular vesicles by cerebrolysin® and donepezil. |
2022-09-26 |
2023-08-14 |
Not clear |
| Simon A Levy, Gabrielle Zuniga, Elias M Gonzalez, David Butler, Sally Temple, Bess Fros. Tau Cell reports methods. vol 2. issue 9. 2022-09-26. PMID:36160048. |
tau tau protein aggregates are a defining neuropathological feature of "tauopathies," a group of neurodegenerative disorders that include alzheimer's disease. |
2022-09-26 |
2023-08-14 |
Not clear |
| Alisa Cario, Sanjula P Wickramasinghe, Elizabeth Rhoades, Christopher L Berge. The N-terminal disease-associated R5L Tau mutation increases microtubule shrinkage rate due to disruption of microtubule-bound Tau patches. The Journal of biological chemistry. 2022-09-26. PMID:36162501. |
tau misregulation is associated with a class of neurodegenerative diseases, known as tauopathies, including progressive supranuclear palsy (psp), pick's disease, and alzheimer's disease. |
2022-09-26 |
2023-08-14 |
Not clear |
| Michael L Alosco, Yi Su, Thor D Stein, Hillary Protas, Jonathan D Cherry, Charles H Adler, Laura J Balcer, Charles Bernick, Surya Vamsi Pulukuri, Bobak Abdolmohammadi, Michael J Coleman, Joseph N Palmisano, Yorghos Tripodis, Jesse Mez, Gil D Rabinovici, Kenneth L Marek, Thomas G Beach, Keith A Johnson, Bertrand Russell Huber, Inga Koerte, Alexander P Lin, Sylvain Bouix, Jeffrey L Cummings, Martha E Shenton, Eric M Reiman, Ann C McKee, Robert A Ster. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players. European journal of nuclear medicine and molecular imaging. 2022-09-24. PMID:36152064. |
flourine-18-flortaucipir tau positron emission tomography (pet) was developed for the detection for alzheimer's disease. |
2022-09-24 |
2023-08-14 |
human |